Last reviewed · How we verify
Lupron Depot
Lupron Depot is a GnRH agonist Small molecule drug developed by University of Michigan Rogel Cancer Center. It is currently FDA-approved for Advanced prostate cancer, Endometriosis, Uterine fibroids. Also known as: Leuprolide, Leuprolide acetate.
Lupron Depot is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production by desensitizing the pituitary gland.
Lupron Depot is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone and estrogen production by desensitizing the pituitary gland. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.
At a glance
| Generic name | Lupron Depot |
|---|---|
| Also known as | Leuprolide, Leuprolide acetate |
| Sponsor | University of Michigan Rogel Cancer Center |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Lupron Depot works by initially stimulating GnRH receptors on pituitary gonadotroph cells, causing a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous exposure, the pituitary becomes desensitized, leading to sustained suppression of LH and FSH, which results in dramatically reduced testosterone (in males) and estrogen (in females). This hormonal suppression is used therapeutically in hormone-sensitive cancers and other conditions dependent on sex hormone signaling.
Approved indications
- Advanced prostate cancer
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reaction
- Bone density loss (osteoporosis with long-term use)
- Fatigue
Key clinical trials
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors (PHASE2)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (PHASE2)
- Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (PHASE2)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lupron Depot CI brief — competitive landscape report
- Lupron Depot updates RSS · CI watch RSS
- University of Michigan Rogel Cancer Center portfolio CI
Frequently asked questions about Lupron Depot
What is Lupron Depot?
How does Lupron Depot work?
What is Lupron Depot used for?
Who makes Lupron Depot?
Is Lupron Depot also known as anything else?
What drug class is Lupron Depot in?
What development phase is Lupron Depot in?
What are the side effects of Lupron Depot?
What does Lupron Depot target?
Related
- Drug class: All GnRH agonist drugs
- Target: All drugs targeting GnRH receptor
- Manufacturer: University of Michigan Rogel Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced prostate cancer
- Indication: Drugs for Endometriosis
- Indication: Drugs for Uterine fibroids
- Also known as: Leuprolide, Leuprolide acetate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing